AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction
Authors: Montalescot, G Choussat, R Collet, JP
Citation: G. Montalescot et al., Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction, EUR H J SUP, 3(A), 2001, pp. A3-A7
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis
Authors: Collett, JP Montalescot, G Lesty, C Soria, J Mishal, Z Thoms, D Soria, C
Citation: Jp. Collett et al., Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis, ART THROM V, 21(1), 2001, pp. 142-148
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
Authors: Anderson, KM Califf, RM Stone, GW Neumann, FJ Montalescot, G Miller, DP Ferguson, JJ Willerson, JT Weisman, HF Topol, EJ
Citation: Km. Anderson et al., Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention, J AM COL C, 37(8), 2001, pp. 2059-2065
Limitation of vWf meta-analysis in LMWH comparison - Reply
Authors: Montalescot, G
Citation: G. Montalescot, Limitation of vWf meta-analysis in LMWH comparison - Reply, J AM COL C, 37(7), 2001, pp. 2006-2007
Whole blood viscosity measurement in acute myocardial infarction: feasability and significance
Authors: Philippe, F Lacombe, C Bucherer, C Drobinski, G Montalescot, G Thomas, D
Citation: F. Philippe et al., Whole blood viscosity measurement in acute myocardial infarction: feasability and significance, J MAL VASC, 26(4), 2001, pp. 243-247
Enoxaparin in unstable angina patients with renal failure
Authors: Collet, JP Montalescot, G Choussat, R Lison, L Ankri, A
Citation: Jp. Collet et al., Enoxaparin in unstable angina patients with renal failure, INT J CARD, 80(1), 2001, pp. 81-82
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acutemyocardial infarction.
Authors: Montalescot, G Barragan, P Wittenberg, O Ecollan, P Elhadad, S Villain, P Boulenc, JM Morice, MC Maillard, L Pansieri, M Choussat, R Pinton, P
Citation: G. Montalescot et al., Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acutemyocardial infarction., N ENG J MED, 344(25), 2001, pp. 1895-1903
Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris
Authors: Collet, JP Montalescot, G Lison, L Choussat, R Ankri, A Drobinski, G Sotirov, I Thomas, D
Citation: Jp. Collet et al., Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris, CIRCULATION, 103(5), 2001, pp. 658-663
Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention
Authors: Collet, JP Montalescot, G Lesty, C Mishal, Z Soria, J Choussat, R Drobinski, G Soria, C Pinton, P Barragan, P Thomas, D
Citation: Jp. Collet et al., Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention, CIRCULATION, 103(19), 2001, pp. 2328-2331
Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes
Authors: Agnelli, G Avezum, A Brieger, D Budaj, A Cannon, CP Goldberg, RJ Goodman, S Gulba, DC Granger, C Kennelly, BM Gurfinkel, E Lopez-Sendon, J Klein, W Montalescot, G Van de Werf, F
Citation: G. Agnelli et al., Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes, AM HEART J, 141(2), 2001, pp. 190-199
Economic evaluation of enoxaparin sodium versus heparin in unstable angina- A French sub-study of the ESSENCE trial
Authors: Detournay, B Huet, X Fagnani, F Montalescot, G
Citation: B. Detournay et al., Economic evaluation of enoxaparin sodium versus heparin in unstable angina- A French sub-study of the ESSENCE trial, PHARMACOECO, 18(1), 2000, pp. 83-93
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed - Dynamic and structural approaches by confocal microscopy
Authors: Collet, JP Park, D Lesty, C Soria, J Soria, C Montalescot, G Weisel, JW
Citation: Jp. Collet et al., Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed - Dynamic and structural approaches by confocal microscopy, ART THROM V, 20(5), 2000, pp. 1354-1361
Fibrinogen: a cardiovascular risk factor
Authors: Colas, JL Montalescot, G Tribouilloy, C
Citation: Jl. Colas et al., Fibrinogen: a cardiovascular risk factor, PRESSE MED, 29(34), 2000, pp. 1862-1866
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
Authors: Montalescot, G Collet, JP Lison, L Choussat, R Ankri, A Vicaut, E Perlemuter, K Philippe, F Drobinski, G Thomas, D
Citation: G. Montalescot et al., Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina, J AM COL C, 36(1), 2000, pp. 110-114
A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients
Authors: Montalescot, G Collet, JP Choussat, R Ankri, A Thomas, D
Citation: G. Montalescot et al., A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients, INT J CARD, 72(3), 2000, pp. 293-294
Reducing the risk of vascular disease: Antiplatelet therapy in the new millennium - Introduction
Authors: King, SB Montalescot, G
Citation: Sb. King et G. Montalescot, Reducing the risk of vascular disease: Antiplatelet therapy in the new millennium - Introduction, CLIN CARD, 23(11), 2000, pp. 1-2
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease
Authors: Montalescot, G
Citation: G. Montalescot, Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease, CLIN CARD, 23(11), 2000, pp. 18-22
Low molecular weight heparin after mechanical heart valve replacement
Authors: Montalescot, G Polle, V Collet, JP Leprince, P Bellanger, A Gandjbakhch, I Thomas, D
Citation: G. Montalescot et al., Low molecular weight heparin after mechanical heart valve replacement, CIRCULATION, 101(10), 2000, pp. 1083-1086
Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction
Authors: Choussat, R Montalescot, G Collet, JP Jardel, C Ankri, A Fillet, AM Thomas, D Raymond, J Bastard, JP Drobinski, G Orfila, J Agut, H Thomas, D
Citation: R. Choussat et al., Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction, AM J CARD, 86(4), 2000, pp. 379-384
Spontaneous late improvement of myocardial viability in the chronic infarct zone is possible, depending on persistent TIMI 3 flow and a low grade stenosis of the infarct artery
Authors: Faraggi, M Montalescot, G Sarda, L Heintz, JF Doumit, D Drobinski, G Sotirov, I Le Guludec, D Thomas, D
Citation: M. Faraggi et al., Spontaneous late improvement of myocardial viability in the chronic infarct zone is possible, depending on persistent TIMI 3 flow and a low grade stenosis of the infarct artery, HEART, 81(4), 1999, pp. 424-430
Acute myocarditis presenting as acute myocardial infarction and sudden death with complete atrioventricular block: Value of antimyosin scintigraphy
Authors: Vilain, D Collet, JP Sarda, L Choussat, R Montalescot, G Le Guludec, D Faraggi, M
Citation: D. Vilain et al., Acute myocarditis presenting as acute myocardial infarction and sudden death with complete atrioventricular block: Value of antimyosin scintigraphy, J NUCL CARD, 6(5), 1999, pp. 547-548
Low molecular weight heparins in the cardiac catheterization laboratory
Authors: Montalescot, G Cohen, M
Citation: G. Montalescot et M. Cohen, Low molecular weight heparins in the cardiac catheterization laboratory, J THROMB TH, 7(3), 1999, pp. 319-323
IT FITS! (Intelligence transfer: From images to solutions) intracoronary stenting of a myocardial bridge
Authors: Drobinski, G Sotirov, Y Collet, JP Lison, L Montalescot, G
Citation: G. Drobinski et al., IT FITS! (Intelligence transfer: From images to solutions) intracoronary stenting of a myocardial bridge, J INTERV CA, 12(5), 1999, pp. 395-396
New anticoagulants
Authors: Choussat, R Montalescot, G
Citation: R. Choussat et G. Montalescot, New anticoagulants, REV MAL RES, 16(5BIS), 1999, pp. 985-995
Low-molecular-weight heparin in unstable angina and infarction without Q wave
Authors: Choussat, R Montalescot, G
Citation: R. Choussat et G. Montalescot, Low-molecular-weight heparin in unstable angina and infarction without Q wave, PRESSE MED, 28(21), 1999, pp. 1128-1134
Risultati: 1-25 | 26-27